Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645238 | PMC |
| http://dx.doi.org/10.4103/aian.aian_53_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anatomical, behavioral, and cognitive teratogenicity associated with valproic acid: a systematic review.
CNS Spectr
December 2024
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Background: Recent guidance from UK health authorities strongly cautions against the use of valproic acid (VPA) in persons under 55 because of reevaluated risk of teratogenicity.
Objective: To summarize the extant literature documenting VPA-associated anatomical, behavioral, and cognitive teratogenicity.
Method: Pubmed, Medline, Cochrane Library, PsychInfo, Embase, Scopus, Web of Science, and Google Scholar were searched in accordance with PRISMA guidelines.
Neuroleptic malignant syndrome in Huntington disease.
Eur J Neurol
December 2024
Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy.
Article Synopsis
- A study evaluated the prevalence of neuroleptic malignant syndrome (NMS) in Huntington disease (HD) patients, finding that it is rarely reported despite the use of dopamine receptor blocking agents (DRBAs).
- Researchers reviewed patient data and case literature to assess NMS occurrences in a cohort of HD patients treated with DRBAs and tetrabenazine (TBZ).
- Results indicated only one diagnosed case of NMS among 5,108 patients, suggesting underreporting and highlighting critical risk factors like advanced disease stage and medication management issues.
Migraine treatment: Position paper of the French Headache Society.
Rev Neurol (Paris)
December 2024
Department of Neurology, Gui-de-Chauliac Hospital, CHU de Montpellier, University of Montpellier, 34000 Montpellier, France.
The French migraine management recommendations were published in 2021. However, in the last three years, new data have come to light and new drugs have been approved (eptinezumab, rimegepant and atogepant) by the European Medicines Agency that require us to take a position on their use and to update certain elements of the recommendations. The first important message concerns the position of the French Headache Society on the use of preventive treatments (monoclonal antibodies and gepants) targeting the calcitonin gene-related peptide (CGRP) pathway.
View Article and Find Full Text PDFValproate use in psychiatry: New caution for an old friend?
Eur Neuropsychopharmacol
November 2024
3(rd) Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Greece. Electronic address:
Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals.
Br J Psychiatry
November 2024
Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan.
Article Synopsis
- * It investigated the impact of titration speed, use of other medications, gender, and obesity on the risk of developing fever among Japanese patients with treatment-resistant schizophrenia.
- * Results showed that faster titration and male gender significantly increased fever risk, while obesity accelerated the onset of fever, highlighting the importance of careful monitoring during clozapine treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!